0001209191-19-025789.txt : 20190424 0001209191-19-025789.hdr.sgml : 20190424 20190424180419 ACCESSION NUMBER: 0001209191-19-025789 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190422 FILED AS OF DATE: 20190424 DATE AS OF CHANGE: 20190424 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: George Simeon CENTRAL INDEX KEY: 0001595117 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38871 FILM NUMBER: 19764829 MAIL ADDRESS: STREET 1: 161 WASHINGTON STREET STREET 2: SUITE 500 CITY: CONSHOHOCKEN STATE: PA ZIP: 19428 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Turning Point Therapeutics, Inc. CENTRAL INDEX KEY: 0001595893 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463826166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 225 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-926-5251 MAIL ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 225 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, Inc. DATE OF NAME CHANGE: 20181018 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, INC DATE OF NAME CHANGE: 20140106 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-04-22 0 0001595893 Turning Point Therapeutics, Inc. TPTX 0001595117 George Simeon C/O S.R.ONE, LIMITED 161 WASHINGTON STREET, SUITE 500 CONSHOHOCKEN PA 19428 1 0 0 0 Common Stock 2019-04-22 4 C 0 1120730 A 1120730 I By S.R.One, Limited Common Stock 2019-04-22 4 C 0 546820 A 1667550 I By S.R.One, Limited Common Stock 2019-04-22 4 P 0 325000 18.00 A 1992550 I By S.R.One, Limited Stock Option (right to buy) 27.06 2019-04-22 4 A 0 15000 0.00 A 2029-04-21 Common Stock 15000 15000 D Series C Preferred Stock 2019-04-22 4 C 0 4314809 0.00 D Common Stock 1120730 0 I By S.R. One, Limited Series D Preferred Stock 2019-04-22 4 C 0 2105259 0.00 D Common Stock 546820 0 I By S.R.One, Limited Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date. S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of the shares reported herein. Simeon J. George holds the title of Vice President at S.R. One, Limited and is an employee of GlaxoSmithKline LLC, a wholly-owned subsidiary of GlaxoSmithKline plc. Mr. George disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. The shares were purchased at the Issuer's initial public offering. The option will become fully vested on the date of the Issuer's 2020 annual meeting of stockholders. As a Vice President of S.R. One, Limited and an employee of GlaxoSmithKline LLC, Simeon George is obligated to transfer any shares issued under the stock option to S.R One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. /s/ Brian Baker, Attorney-in-Fact 2019-04-24